AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Tela Bio Inc (NASDAQ:TELA)
1.85 USD
-0.100 5.128%| Previous Close (in USD) | 1.95 |
|---|---|
| Change | -0.100 5.128% |
| 52 W H/L (in USD) | 11.260/4.235 |
| EBITDA (in USD) | -44.4M |
| PE Ratio | -- |
| Volume | 69316 |
| Diluted Eps TTM | -1.61 |
| Total Assets (in USD) | 78.048M |
|---|---|
| Total Liabilities (in USD) | 59.167M |
| Revenue TTM (in USD) | 63.147M |
| Cash (in USD) | 46.729M |
| Market Cap (in USD) | 141.522 M |
| Revenue Per Share TTM | 2.608 |
| Gross Profit TTM (in USD) | 27.848M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Employees: 227
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Antony Koblish | Co-founder, Pres, CEO & Director | 1966 |
| 2. | Dr. E. Skott Greenhalgh Ph.D. | Chief Technology Officer | 1968 |
| 3. | Mr. Peter C. Murphy | Chief Commercial Officer | 1973 |
| 4. | Mr. Roberto E. Cuca J.D. | CFO & COO | 1968 |
| 5. | Ms. Megan Smeykal | VP, Corp. Controller, Chief Accounting Officer & Principal Accounting Officer | 1976 |
| 6. | Mr. D. Taylor Ocasio | Gen. Counsel | NA |
| 7. | Mr. Christopher H. Smith | Sr. VP of Sales | 1961 |
| 8. | Ms. Jennifer Lou Armstrong | Sr. VP of HR | 1970 |
| 9. | Mr. Michael Leonard | Sr. VP of Technical Operations | NA |
| 10. | Mr. Paul Talmo | Chief Strategic Officer | NA |
Peers
Sector: Healthcare
Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ABT
Abbott Laboratories |
-0.365 0.273% | 134.79 | 37.150 | 23.148 | 4.666 | 4.975 | 4.878 | 19.381 |
|
SYK
Stryker Corporation |
+0.280 0.073% | 385.42 | 44.070 | 24.938 | 5.509 | 6.118 | 6.050 | 25.731 |
|
MDT
Medtronic PLC |
+0.063 0.072% | 87.29 | 26.600 | 15.873 | 3.354 | 2.083 | 3.897 | 14.117 |
|
BSX
Boston Scientific Corp |
-1.710 1.663% | 103.1 | 68.170 | 24.570 | 5.855 | 4.265 | 6.462 | 26.799 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -44.296M | -33.276M | -28.794M | -22.425M | -21.092M |
| Minority Interest | - | - | - | - | - |
| Net Income | -44.337M | -36.11M | -31.878M | -25.803M | -21.092M |
| Selling General Administrative | 13.862M | 12.459M | 10.143M | 6.223M | 4.899M |
| Gross Profit | 27.044M | 18.813M | 11.234M | 9.272M | 2.942M |
| Reconciled Depreciation | 1.187M | 0.535M | 0.525M | 0.582M | 1.248M |
| Ebit | -39.007M | -29.451M | -25.275M | -19.162M | -19.872M |
| Ebitda | -39.017M | -29.679M | -25.23M | -18.811M | -18.624M |
| Depreciation And Amortization | -0.01M | -0.228M | 0.045M | 0.351M | 1.248M |
| Operating Income | -39.007M | -29.451M | -25.275M | -19.162M | -17.782M |
| Other Operating Expenses | 80.425M | 58.914M | 43.488M | 34.608M | 28.216M |
| Interest Expense | 4.051M | 3.597M | 3.564M | 3.609M | 1.802M |
| Tax Provision | - | - | - | - | - |
| Interest Income | - | - | - | 3.614M | 1.558M |
| Net Interest Income | -4.051M | -3.597M | -3.564M | -3.609M | -1.802M |
| Income Tax Expense | 0.041M | 2.834M | 3.084M | 3.378M | -1.508M |
| Total Revenue | 41.418M | 29.463M | 18.213M | 15.446M | 8.274M |
| Total Operating Expenses | 66.051M | 48.264M | 36.509M | 28.434M | 22.884M |
| Cost Of Revenue | 14.374M | 10.65M | 6.979M | 6.174M | 5.332M |
| Total Other Income Expense Net | -5.289M | -3.825M | -3.519M | -3.263M | 0.652M |
| Net Income From Continuing Ops | -44.296M | -33.276M | -28.794M | -22.425M | -21.092M |
| Net Income Applicable To Common Shares | -44.296M | -33.276M | -28.794M | -30.208M | -29.915M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 78.048M | 67.855M | 62.544M | 86.458M | 67.922M |
| Intangible Assets | 2.119M | 2.499M | 2.303M | 2.607M | 2.911M |
| Other Current Assets | 2.098M | 2.015M | 3.232M | 2.241M | 2.308M |
| Total Liab | 59.167M | 53.55M | 42.446M | 37.432M | 36.96M |
| Total Stockholder Equity | 18.881M | 14.305M | 20.098M | 49.026M | 30.962M |
| Other Current Liab | 14.735M | 10.529M | 8.161M | 5.953M | 3.542M |
| Common Stock | 0.024M | 0.019M | 0.015M | 0.014M | 0.011M |
| Capital Stock | 0.024M | 0.019M | 0.015M | 0.014M | 0.011M |
| Retained Earnings | -320.889M | -274.225M | -229.929M | -196.653M | -167.859M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | - | - |
| Cash | 46.729M | 42.019M | 43.931M | 74.394M | 45.302M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 16.967M | 12.403M | 10.575M | 6.605M | 6.713M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -3.949M | -2.103M | -12.44M | -43.567M | -15.059M |
| Short Term Debt | 0.565M | 0.34M | - | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 42.78M | 39.916M | 31.491M | 30.827M | 30.243M |
| Other Stockholder Equity | 339.655M | 288.361M | 250.064M | 245.736M | 130.907M |
| Property Plant Equipment | - | 1.682M | 1.186M | 0.626M | 0.677M |
| Total Current Assets | 71.726M | 62.447M | 59.055M | 83.225M | 64.334M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | 0M | 9.285M |
| Net Receivables | 9.737M | 6.621M | 4.234M | 2.683M | 2.836M |
| Long Term Debt | 40.515M | 39.916M | 31.491M | 30.827M | 30.243M |
| Inventory | 13.162M | 11.792M | 7.658M | 3.907M | 4.603M |
| Accounts Payable | 1.667M | 1.534M | 2.414M | 0.652M | 3.171M |
| Accumulated Other Comprehensive Income | 0.091M | 0.15M | -0.052M | -0.071M | -0.019M |
| Non Currrent Assets Other | 0.265M | 1.227M | - | - | 2.911M |
| Non Current Assets Total | 6.322M | 5.408M | 3.489M | 3.233M | 3.588M |
| Capital Lease Obligations | 0.565M | 0.34M | - | - | - |
| Long Term Debt Total | - | 39.916M | 31.491M | - | 30.243M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -1.872M | -0.627M | 9.122M | -11.981M | -9.284M |
| Total Cashflows From Investing Activities | -1.872M | -0.627M | 9.122M | -11.981M | -1.558M |
| Total Cash From Financing Activities | 40.852M | 0.585M | 44.409M | 65.532M | 27.414M |
| Net Income | -44.296M | -33.276M | -28.794M | -22.425M | -21.092M |
| Change In Cash | -1.912M | -30.463M | 29.092M | 28.024M | 5.932M |
| Begin Period Cash Flow | 43.931M | 74.394M | 45.302M | 17.278M | 11.346M |
| End Period Cash Flow | 42.019M | 43.931M | 74.394M | 45.302M | 17.278M |
| Total Cash From Operating Activities | -40.748M | -30.432M | -24.456M | -25.523M | -19.924M |
| Depreciation | 1.187M | 0.535M | 0.525M | 0.582M | 1.248M |
| Other Cashflows From Investing Activities | -1M | - | - | -9.284M | 0.004M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -6.073M | -5.194M | -0.62M | -1.839M | -4.757M |
| Sale Purchase Of Stock | 0.05M | 0.038M | 0.034M | 65.532M | 3.983M |
| Other Cashflows From Financing Activities | 36.402M | 0.547M | -0.347M | 14.381M | 46.146M |
| Capital Expenditures | 1.872M | 0.627M | 0.167M | 2.697M | 1.562M |
| Change In Working Capital | -5.763M | -3.469M | -0.086M | -6.235M | -4.455M |
| Other Non Cash Items | 4.135M | 2.103M | 1.841M | 2.093M | 2.936M |
| Free Cash Flow | -42.62M | -31.059M | -24.623M | -28.22M | -21.486M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 643290 |
| 2. | Federated Hermes Kaufmann Growth | 1 year ago | 500000 |
| 3. | Federated Hermes Kaufmann R | 1 year ago | 500000 |
| 4. | iShares Russell 2000 ETF | 1 year ago | 359799 |
| 5. | Paradigm Micro-Cap | 1 year ago | 300000 |
| 6. | Kennedy Micro Cap | 1 year ago | 292343 |
| 7. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 226799 |
| 8. | Federated Hermes Kaufmann Small Cap Grow | 1 year ago | 200000 |
| 9. | Federated Hermes Kaufmann Small Cap A | 1 year ago | 200000 |
| 10. | Fidelity Small Cap Index | 1 year ago | 163514 |
| 11. | Jacob Discovery Fd Instl | 1 year ago | 139775 |
| 12. | iShares Russell 2000 Growth ETF | 1 year ago | 132146 |
| 13. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 113375 |
| 14. | Calamos Timpani Small Cap Growth I | 1 year ago | 110593 |
| 15. | Timpani Small Cap Growth Equity | 1 year ago | 110593 |
| 16. | Kennedy Micro Cap Opportunities | 1 year ago | 88062 |
| 17. | Fidelity Extended Market Index | 1 year ago | 87172 |
| 18. | CREF Stock R1 | 1 year ago | 69520 |
| 19. | Vanguard Russell 2000 ETF | 1 year ago | 61402 |
| 20. | State St Russell Sm Cap® Indx SL Cl I | 1 year ago | 58500 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Essex Woodlands Health Ventures | 1 year ago | 4110709 |
| 2. | Orbimed Advisors, LLC | 1 year ago | 2835542 |
| 3. | First Light Asset Management, LLC | 1 year ago | 2554641 |
| 4. | Nantahala Capital Management, LLC | 1 year ago | 2195732 |
| 5. | AIGH Capital Management, LLC | 1 year ago | 1377945 |
| 6. | BlackRock Inc | 1 year ago | 1078056 |
| 7. | Vanguard Group Inc | 1 year ago | 998853 |
| 8. | Pentwater Capital Management LP | 1 year ago | 990000 |
| 9. | SILVERARC CAPITAL MANAGEMENT, LLC | 1 year ago | 795080 |
| 10. | Federated Hermes Inc | 1 year ago | 712300 |
| 11. | UBS Group AG | 1 year ago | 688922 |
| 12. | Paradigm Capital Management, Inc. | 1 year ago | 498500 |
| 13. | Kennedy Capital Management Inc | 1 year ago | 382214 |
| 14. | Geode Capital Management, LLC | 1 year ago | 346662 |
| 15. | Worth Venture Partners, LLC | 1 year ago | 345331 |
| 16. | State Street Corporation | 1 year ago | 320543 |
| 17. | Stonepine Capital Management Llc | 1 year ago | 317782 |
| 18. | Perkins Capital Management Inc | 1 year ago | 210250 |
| 19. | Jacob Asset Mgmt Of NY LLC | 1 year ago | 159775 |
| 20. | Northern Trust Corp | 1 year ago | 135092 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...